ICER releases list of potential review topics in 2018

ICER releases list of potential review topics in 2018 PharmacoEconomics & Outcomes News 784, p3 - 12 Aug 2017 ICER releases list of potential review topics in 2018 The Institute for Clinical and Economic Review (ICER) has published a preliminary list of prescription drug review topics for 2018, which includes some for cancers, migraine, and cystic fibrosis. ICER draws its list of topics for review from its horizon scans of new and emerging therapies, conversations with stakeholders, and suggestions submitted from the public. Topic selection criteria includes the projected timing and likelihood of FDA approval, and whether a review of the evidence is likely to result in specific actions to improve clinical practice and/or policy. The list, which may change, includes: voretigene neparvovec [Spark Therapeutics] for vision loss associated with biallelic RPE65-mediated retinal disease; axicabtagene ciloleucel [Kite Pharmaceuticals] and tisagenlecleucel-t [Novartis] for B-cell leukemia and lymphoma; apalutamide [Johnson & Johnson] for prostate cancer CTP-modified human growth hormone [Opko/ Pfizer] for short stature/growth hormone deficiency; damoctocog-α pegol [Bayer], emicizumab [Roche] for haemophilia type A; erenumab [Amgen], fremanezumab [Teva], and galcanezumab [Eli Lilly] for migraine and other headaches; lanadelumab [Shire] for hereditary angioedema; larotrectinib [LOXO Oncology/Array BioPharma] for solid tumors expressing a specific biomarker; and, tezacaftor in combination with ivacaftor [Vertex] for cystic fibrosis. The next topic announcement is expected mid- August. Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Announces Potential Topics for Review in 2018. Internet Document : 26 Jul 2017. Available from: URL: https://icer-review.org/announcements/icer-topic- selection-2018/ 803261766 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

ICER releases list of potential review topics in 2018

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/icer-releases-list-of-potential-review-topics-in-2018-r8rjcD29Ve
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4214-2
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial